Valuation: Voyageur Pharmaceuticals Ltd.

Market Cap 3.62Cr 2.63Cr 2.25Cr 2.11Cr 1.93Cr 251.65Cr 3.67Cr 25Cr 9.71Cr 126.42Cr 9.88Cr 9.66Cr 418.13Cr P/E 2024
-5.24x
P/E 2025 -7.5x
Enterprise Value 3.6Cr 2.61Cr 2.24Cr 2.09Cr 1.92Cr 250.05Cr 3.65Cr 25Cr 9.65Cr 125.61Cr 9.81Cr 9.6Cr 415.47Cr EV / Sales 2024
-
EV / Sales 2025 2,42,35,81,172x
Free-Float
93.07%
Yield 2024 *
-
Yield 2025 -
10/08 Voyageur Pharmaceuticals Ltd. Advances Mueller Iodine Extraction Process with 99.8% Purity Results and Planned Field Pilot Testing CI
25/07 Voyageur Pharmaceuticals Ltd. Reports Earnings Results for the Second Quarter and Six Months Ended May 31, 2026 CI
19/06 Voyageur Pharmaceuticals Evaluates Three Locations in the United States for Integrated Iodine and Barium Contrast Media Manufacturing Facility CI
10/06 Voyageur Pharmaceuticals Ltd Submits Multi-Year Area-Based Exploration Permit Application for Bulk Sampling and Feasibility Support At Frances Creek Barite Project CI
05/06 Voyageur Pharmaceuticals Ltd. announced that it has received CAD 5.005278 million in funding CI
01/05 Voyageur Pharmaceuticals Ltd. announced that it expects to receive CAD 10 million in funding CI
01/05 Voyageur Pharmaceuticals Ltd. cancelled the transaction announced on March 24, 2026 CI
24/04 Voyageur Pharmaceuticals Ltd. Reports Earnings Results for the First Quarter Ended February 28, 2026 CI
27/03 Voyageur Pharmaceuticals Ltd. Reports Earnings Results for the Full Year Ended November 30, 2025 CI
27/03 Voyageur Pharmaceuticals Ltd. Auditor Raises 'Going Concern' Doubt CI
24/03 Voyageur Pharmaceuticals Ltd. announced that it expects to receive CAD 7.5 million in funding CI
04/03 Voyageur Pharmaceuticals Ltd. Announces Independent Laboratory Test Results for Its Barium Sulfate Active Pharmaceutical Ingredient CI
23/02 Voyageur Pharmaceuticals Announces Collaboration with Bayer Aktiengesellschaft CI
1 day-3.13%
1 week-3.12%
Current month+19.23%
1 month+3.33%
3 months+63.16%
6 months-11.43%
Current year-8.82%
1 week 0.16
Extreme 0.155
0.16
1 month 0.12
Extreme 0.125
0.18
Current year 0.07
Extreme 0.07
0.19
1 year 0.07
Extreme 0.07
0.2
3 years 0.04
Extreme 0.035
0.36
5 years 0.04
Extreme 0.035
0.36
10 years 0.04
Extreme 0.035
0.36
Manager TitleAgeSince
Chief Executive Officer - 01/07/2019
Director of Finance/CFO - 17/08/2022
Chief Tech/Sci/R&D Officer - 17/09/2024
Director TitleAgeSince
Director/Board Member - 06/12/2017
Director/Board Member - 01/07/2019
Chairman - 30/04/2025
Date Insider Type Main position Quantity % Market Cap.
06/03/26 Option 8,00,000 0.4480%
06/03/26 Option

Director

41,842 0.0234%
20/08/25 Option 11,20,000 0.6981%
Change 5-day change 1-year change 3-year change Capi.($)
-3.12%-3.12%-8.82%+287.50% 2.63Cr
+0.88%+6.38%+76.86%+128.23% 1,10900Cr
+1.07%+3.80%+51.03%+61.48% 64TCr
+1.20%+6.21%+26.47%+76.45% 46TCr
+1.02%+3.67%+43.14%+47.27% 37TCr
+0.85%+2.97%+24.48%+42.54% 30TCr
+1.26%+4.54%+2.20%+14.84% 26TCr
+1.88%+5.81%+48.54%+68.52% 23TCr
+1.59%+0.87%-12.95%-51.91% 20TCr
+1.87%+5.61%+25.81%+92.42% 18TCr
Average +0.69%+2.12%+27.68%+76.73% 37.61TCr
Weighted average by Cap. +1.03%+3.26%+44.58%+72.65%

Financials

2024 2025
Net sales - 0.01 0.01 0.01 0.01 0.01 0.81 0.01 0.08 0.03 0.41 0.03 0.03 1.35
Net income -17.07L -12.4L -10.62L -10L -9L -12Cr -17.3L -1.17Cr -45.79L -5.96Cr -46.56L -45.54L -20Cr -35.33L -25.66L -21.98L -20.56L -18.82L -25Cr -35.79L -2.43Cr -94.74L -12Cr -96.33L -94.24L -41Cr
Net Debt -1L -81.8T -70.07T -65.56T -60.02T -78.27L -1L -8L -3L -39.32L -3L -3L -1.3Cr -2L -2L -1L -1L -1L -1.6Cr -2L -15.86L -6L -80.48L -6L -6L -2.66Cr
Logo Voyageur Pharmaceuticals Ltd.
Voyageur Pharmaceuticals Ltd. is a Canada-based company engaged in the development of barium and iodine active pharmaceutical ingredients (API) and imaging contrast agents for medical radiology. It focuses on vertically integrating the barium and iodine contrast markets. In addition, Voyageur is pursuing the development of new endo fullerene drugs. Its products include SmoothX, SmoothHD, SmoothLD, VisionHD, VisionLD and V-Gas. SmoothX (2%w/v) is a contrast medium for use in computed tomography (CT) of the gastrointestinal tract. VisionHD is a high-density (98% w/w) barium powder suspension tailored for double-contrast radiographic examination of the gastrointestinal tract, esophagus, stomach and duodenum. At the core of its operations, the Company also owns a 100% interest in the Frances Creek Project, which boasts a mineral suitable for the pharmaceutical marketplace that is intended to replace the current synthetic products with quality imaging products.
Employees
-
Date Price Change Volume
21/26/21 CA$0.1550 -3.12% 17,900
20/26/20 CA$0.1600 -3.03% 13,500
19/26/19 CA$0.1650 +3.13% 21,658
18/26/18 CA$0.1600 -3.03% 2,63,000
17/26/17 CA$0.1650 +3.13% 1,40,707

Annual profits - Rate of surprise